Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization: Context Therapeutics Inc (CNTX)

Context Therapeutics Inc (CNTX) - corporate logo

The EV/EBITDA price chart allows for a valuation of Context Therapeutics (CNTX), which relies on external contractors for trials and protein synthesis. The current metric stands at 0.00. Context Therapeutics (CNTX) is creating a comprehensive environment for the therapy of uterine and breast tumors by implementing innovative targeted methods. Thanks to a unique scientific portfolio, the brand enjoys a well-deserved reputation among medical experts and investors.

CNTX Context Therapeutics Inc.: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/12/2026

contexttherapeutics.com - analytical breakdowns and key metrics (CNTX)

- stock price and consensus target price:
Stock Quotes Context Therapeutics Inc.|CNTX - Consensus Target
- company stock exchange capitalization indicators:
Market Value CNTX|CNTX - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Context Therapeutics|CNTX - Company Net Assets|Market Capitalization to Book Value Ratio contexttherapeutics.com|CNTX - Company Assets
- debt and liquidity data:
Debt to Equity Context Therapeutics|CNTX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Context Therapeutics Inc.|CNTX - Company Total Debt|Debt to Book Capitalization Ratio CNTX|CNTX - Long-Term Debt|Company Short-Term Debt Context Therapeutics|Quick Liquidity Indicator contexttherapeutics.com
- business earnings and investment ratios data:
CNTX - Profit After Payment of Taxes|Projected Future Earnings Context Therapeutics|CNTX - Market Cap to Earnings|Projected Price to Earnings Context Therapeutics Inc.|CNTX - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio CNTX|CNTX - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Context Therapeutics|CNTX - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months contexttherapeutics.com|CNTX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Context Therapeutics
Analysis of all company metrics:CNTX (Context Tx)
Original product of contexttherapeutics.com

The investor utilizes this indicator to determine the business's enterprise value by combining market capitalization with net debt and comparing the result to earnings before interest, taxes, depreciation, and amortization. For Context Therapeutics (CNTX), which holds unique inhibitors in the inelastic demand segment of female oncology, the EV/EBITDA value accounting for total debt reflects the company's ability to monetize its pricing power to service its obligations.

Competitor analysis

Merus Corp - Enterprise Value to EBITDA Ratio|IMMP - Enterprise Value to EBITDA Ratio|ANIX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA atossatherapeutics.com|mersana.com (MRSN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio BriaCell Therapeutics Corp.|EPIX (ESSA Pharma, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA QT Imaging, Inc. QTI